Xeris Biopharma expects full-year 2025 revenue above estimates
Source: SeekingAlpha
2026-01-08 07:51:36 ET
More on Xeris Pharmaceuticals
- Xeris Biopharma: A Balanced Perspective Needed (Rating Downgrade)
- Xeris Biopharma Holdings, Inc. (XERS) Q3 2025 Earnings Call Transcript
- Xeris Biopharma: Quality Business At A Premium Valuation
- Xeris raises 2025 revenue guidance to $285M-$290M as RECORLEV revenue more than doubles year-over-year
- Xeris Pharmaceuticals Q3 2025 Earnings Preview
Read the full article on Seeking Alpha
For further details see:
Xeris Biopharma expects full-year 2025 revenue above estimates
Xeris Pharmaceuticals Inc.
NASDAQ: XERS
XERS Trading
0.53% G/L:
$5.735 Last:
546,614 Volume:
$5.73 Open:
XERS Latest News
XERS Stock Data
$1,185,529,045
155,188,988
4.48%
76
N/A
Biotechnology & Life Sciences
Healthcare
US
Chicago
